Search results for "Monoamine Oxidase Inhibitors"

showing 7 items of 17 documents

Effects of brofaremine (CGP 11 305A), a short-acting, reversible, and selective inhibitor of MAO-A on sleep, nocturnal penile tumescence and nocturna…

1987

The effects of brofaremine (CGP 11 305A), a short-acting, reversible and selective inhibitor of MAO-A, on sleep, nocturnal penile tumescence (NPT) and hormonal secretion during the night were studied during a long-term trial. Three healthy males underwent sleep-EEG and NPT recordings during consecutive nights (1) under placebo, (2) under stepwise increasing dosages of brofaremine and (3) under placebo after withdrawal. Hormone profiles were sampled during selected nights to analyze the plasma concentration of cortisol, HGH, prolactin, testosterone, LH and FSH. REM sleep was suppressed markedly under 150 mg brofaremine, while stages 1 and 2 increased. In comparison to the effect of irreversi…

PharmacologyAdultMalemedicine.medical_specialtyMonoamine Oxidase Inhibitorsbusiness.industryPenile ErectionSleep REMElectroencephalographyNocturnalPlaceboSleep in non-human animalsREM reboundProlactinHormonesEndocrinologyPiperidinesInternal medicineNocturnal penile tumescencemedicineHumansbusinessSleepTestosteroneHormonePsychopharmacology
researchProduct

Antidepressant drugs and memory: Insights from animal studies

2007

This is a selective review of the literature concerning the effects of antidepressant drugs on animal memory, which was performed with the aid of the PubMed database. Monoamine oxidase inhibitors tend to either have no effect on memory or result in its improvement. Studies with cyclic antidepressants have reported no effect or, more often, memory impairments. Pre-training administration of selective serotonin reuptake inhibitors (SSRIs) has been shown to have either no effect on memory or undermine it (with some isolated exceptions, in which improvements have been recorded), while post-training administration of SSRIs has been demonstrated to improve memory or have no effect. A small group …

PharmacologyMonoamine Oxidase InhibitorsMonoamine oxidaseTrazodoneAntidepressive Agents TricyclicSerotonin reuptakePharmacologyAntidepressive AgentsRatsPsychiatry and Mental healthNeurologyMemorymedicineAnimalsConditioning OperantAntidepressantPharmacology (medical)Neurology (clinical)Animal studiesPsychologyNeuroscienceSelective Serotonin Reuptake InhibitorsBiological Psychiatrymedicine.drugEuropean Neuropsychopharmacology
researchProduct

Monoamine Oxidase Inhibition by β-Carbolines: A Quantum Chemical Approach

1979

Monoamine oxidase inhibition by beta-carboline derivatives is related to the energy change, delta E, arising from complex formation between the inhibitor and the enzyme. The energy change was expressed in terms of electronic indexes, which were estimated for a set of aromatic beta-carbolines. The electronic indexes were correlated to the experimental activity indexes by a simplified quantum chemical perturbational treatment with a multiple regression procedure. A characteristic structure for the inhibitor-enzyme complex was derived from the correlation. The molecules are linked by two kinds of bond. One involves the lone pyridine nitrogen pair of beta-carbolines; the other is due to a pi-el…

Quantum chemicalIndole testchemistry.chemical_classificationTryptamineIndolesMonoamine Oxidase InhibitorsChemistryMonoamine oxidaseStereochemistryPharmaceutical ScienceModels BiologicalStructure-Activity Relationshipchemistry.chemical_compoundNon-competitive inhibitionEnzymePyridineQuantum TheoryThermodynamicsMoleculeCarbolinesJournal of Pharmaceutical Sciences
researchProduct

A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial

2021

Background: Safinamide modulates both dopaminergic and glutamatergic systems with positive effects on motor and non-motor symptoms of Parkinson's disease (PD). The drug utilization study SYNAPSES was designed to investigate the use of safinamide in routine clinical practice, as recommended by the European Medicines Agency. Objective: To describe the occurrence of adverse events in PD patients treated with safinamide in real-life conditions. Methods: The SYNAPSES trial is an observational, European, multicenter, retrospective-prospective cohort study. Patients were followed up to 12 months with analyses performed in the overall population and in patients aged >75 years, with relevant comorbi…

Research ReportMale0301 basic medicineBenzylaminesParkinson's diseaseOutcome AssessmentParkinson's diseaseComorbidityDiseaseReal-life evaluationchemistry.chemical_compound0302 clinical medicineOutcome Assessment Health Care80 and overMAO-B inhibitorAged 80 and overSafinamideeducation.field_of_studyAlanineMental DisordersParkinson DiseaseMiddle AgedMAO-B inhibitor; Parkinson's disease; Real-life evaluation; Safinamide; Aged; Aged 80 and over; Alanine; Benzylamines; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Outcome Assessment Health CareEuropeSettore MED/26 - NEUROLOGIAFemaleErratumCohort studymedicine.medical_specialtyMonoamine Oxidase InhibitorsDrug-Related Side Effects and Adverse ReactionsPopulationMEDLINE03 medical and health sciencesCellular and Molecular NeuroscienceSafinamideInternal medicinemedicineHumansAdverse effecteducationAgedRetrospective Studiesbusiness.industryMAO-B inhibitor; Parkinson's disease; Real-life evaluation; Safinamidemedicine.diseaseHealth Care030104 developmental biologychemistryParkinson’s diseaseObservational studyNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up StudiesJournal of Parkinson's Disease
researchProduct

Neuronal and extraneuronal uptake and efflux of catecholamines in the isolated rabbit heart

1974

1. Isolated rabbit hearts were perfused with (−)-noradrenaline, (−)-adrenaline and (±)-isoprenaline for various time periods (1–180 min) and then washed with an amine-free medium. The venous concentration of the amine was estimated fluorimetrically during the infusion and after its end, to study removal and efflux, respectively. 2. In untreated hearts and after pretreatment with reserpine the removal had a constant rate over 20–60 min. After pretreatment with pargyline to block monoamine oxidase (MAO), however, the removal of noradrenaline declined exponentially to zero. Inhibition of the neuronal uptake (desipramine) and chemical sympathectomy (6-hydroxydopamine) abolished the removal of n…

medicine.medical_specialtyMonoamine Oxidase InhibitorsReserpineTime FactorsEpinephrineMonoamine oxidaseStimulationModels BiologicalHydroxydopaminesNorepinephrineCatecholaminesHeart RateDesipramineIsoprenalineInternal medicinemedicineAnimalsNeuronsPharmacologyChemistryMyocardiumDesipramineIsoproterenolGeneral MedicineCompartment (chemistry)ReserpinePargylinePerfusionEndocrinologyPargylineRabbitsEffluxHalf-Lifemedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

The neuronal efflux of noradrenaline: Dependency on sodium and facilitation by ouabain

1974

Rabbit hearts were isolated after pretreatment with the MAO inhibitor pargyline and with reserpine and were perfused with 200 ng/ml noradrenaline for 1 h. During the subsequent wash-out with an amine-free solution for 2 h, the neuronal efflux of noradrenaline declined mono-exponentially with a mean halftime of 42 min. Both Na+-free solution and ouabain caused facilitation of the efflux which thereafter declined in a multi-exponential fashion. The maximum facilitation was reached after 3 min of Na+-free perfusion and 25 min after introduction of ouabain. The amount of exogenous noradrenaline accumulated in the heart was only partially released when the extracellular Na+-concentration was nor…

medicine.medical_specialtyMonoamine Oxidase InhibitorsReserpineTime FactorsSodiumchemistry.chemical_elementAdrenergicOuabainNorepinephrineHeart RateInternal medicinemedicineExtracellularAnimalsOuabainNeuronsPharmacologyMyocardiumSodiumGeneral MedicineReserpinePargylineEndocrinologyPargylinechemistryRabbitsEffluxPerfusionmedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Release of endogenous 3,4-dihydroxyphenylethylamine and its metabolites from the isolated neurointermediate lobe of the rat pituitary gland. Effects …

1986

: Isolated rat neurointermediate lobes were incubated in vitro. The release of 3,4-dihydroxyphenylethylamine (dopamine, DA), dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and methoxyphenylethanol (MOPET) was determined by HPLC with electrochemical detection. Under resting conditions, the outflow of metabolites was 35–50 times that of DA. HVA accounted for 50%, DOPAC for 45%, and MOPET for 5% of the metabolites. Although an equivalent of 40–50% of the tissue DA content was released per hour as metabolites, the tissue DA content was not reduced after 110 min of incubation. The spontaneous outflow of DA and its metabolites was not affected by the DA uptake inhibitor GBR 12921 (1…

medicine.medical_specialtyPituitary gland3-Methoxy-4-hydroxyphenylethanolMonoamine Oxidase InhibitorsMonoamine oxidaseDopamineStimulationBiochemistryPiperazinesReuptakeCellular and Molecular Neurosciencechemistry.chemical_compoundPituitary Gland PosteriorDopamineInternal medicinemedicineAnimalsChromatography High Pressure LiquidChemistryCatabolismHomovanillic acidHomovanillic AcidPargylineElectric StimulationRatsKineticsmedicine.anatomical_structureEndocrinologyPargyline34-Dihydroxyphenylacetic AcidFemalemedicine.drugJournal of neurochemistry
researchProduct